共 122 条
[11]
Afshar-Oromieh A(2023)177Lu-PSMA SPECT quantitation at 6 weeks (dose 2) predicts short progression-free survival for patients undergoing 177Lu-PSMA-I&T therapy J Nucl Med 11 e0162303-247
[12]
Hetzheim H(2016)Investigating the effect of ligand amount and injected therapeutic activity: a simulation study for 177Lu-labeled PSMA-targeting peptides PLoS ONE 76 63-1176
[13]
Kratochwil C(2013)Identification, characterization and suppression of side-products formed during the synthesis of high dose Appl Radiat Isot 62 1482-undefined
[14]
Benesova M(2021)Ga-DOTA-TATE J Nucl Med 15 522-undefined
[15]
Eder M(2022)PSMA-targeted therapeutics: a tale about law and economics Pharmaceuticals 31 1-undefined
[16]
Neels OC(2016)Development and validation of analytical methods for radiochemical purity of 177Lu-PSMA-1 Eur J Pharm Sci 32 887-undefined
[17]
Bu T(2011)From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial Nucl Med Commun 93 63-undefined
[18]
Zhang L(2021)Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system Nucl Med Biol 63 1199-undefined
[19]
Yu F(2022)Development and validation of the HPLC method for quality control of radiolabelled DOTA-TATE and DOTA-TOC preparations J Nucl Med 50 244-undefined
[20]
Yao X(2022)Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry J Nucl Med Technol 4 63-undefined